← Back to Search

Long-Term Safety of Troriluzole for OCD

Phase 3
Waitlist Available
Research Sponsored by Biohaven Pharmaceuticals, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
It is required that all women of child-bearing potential (WOCBP) who are sexually active agree to use two methods of contraception for the duration of the study
Key
Timeline
Screening 3 weeks
Treatment Varies
Follow Up change from baseline to week 48
Awards & highlights

Study Summary

This trial will study the safety and effectiveness of a new drug for OCD over a long period of time.

Who is the study for?
This trial is for individuals who have completed previous studies BHV4157-302 or BHV4157-303, are medically stable, and if capable of childbearing, agree to use two contraception methods. It's not for those with recent suicidality or participation in other drug trials within specified time frames.Check my eligibility
What is being tested?
The study tests the long-term safety of Troriluzole as an additional treatment for OCD. Participants will continue from prior studies to assess how well they tolerate this medication over a more extended period.See study design
What are the potential side effects?
While specific side effects aren't listed here, 'tolerability' suggests monitoring for any adverse reactions patients might experience while taking Troriluzole over a long duration.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I agree to use two forms of birth control during the study.
Select...
I am unsure what 'Key' refers to in this context.
Select...
I agree to use two forms of birth control during the study.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~change from baseline to week 48
This trial's timeline: 3 weeks for screening, Varies for treatment, and change from baseline to week 48 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Clomipramine

Trial Design

1Treatment groups
Experimental Treatment
Group I: Troriluzole (BHV-4157)Experimental Treatment1 Intervention
200 mg daily first 2 weeks, 280 daily for following 46 weeks

Find a Location

Who is running the clinical trial?

Biohaven Pharmaceuticals, Inc.Lead Sponsor
47 Previous Clinical Trials
35,935 Total Patients Enrolled
3 Trials studying Obsessive-Compulsive Disorder
1,826 Patients Enrolled for Obsessive-Compulsive Disorder

Media Library

Troriluzole (BHV-4157) Clinical Trial Eligibility Overview. Trial Name: NCT04708834 — Phase 3
Obsessive-Compulsive Disorder Research Study Groups: Troriluzole (BHV-4157)
Obsessive-Compulsive Disorder Clinical Trial 2023: Troriluzole (BHV-4157) Highlights & Side Effects. Trial Name: NCT04708834 — Phase 3
Troriluzole (BHV-4157) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04708834 — Phase 3
Obsessive-Compulsive Disorder Patient Testimony for trial: Trial Name: NCT04708834 — Phase 3

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

If a person is younger than 45, can they participate in this medical experiment?

"The recruitment process for this clinical trial looks for individuals who have not yet reached the age of 65 and are above the age of majority."

Answered by AI

What are the possible risks associated with taking Troriluzole (BHV-4157)?

"Troriluzole (BHV-4157) has been given a safety score of 3. This is due to the fact that this is a Phase 3 trial, which means that there is both some efficacy data and multiple rounds of safety data supporting its use."

Answered by AI

Could you please tell me how many different medical clinics are running this study today?

"One hundred clinical trial sites are currently running this study in locations including Mesquite, Bangor, Calgary, and other cities. To cut down on travel, it is advised that you pick the location nearest to you."

Answered by AI

Are there any other existing reports of Troriluzole's (BHV-4157) efficacy?

"First studied in 2016 at UCLA, troriluzole has completed 2 clinical trials with 6 more underway. The majority of these medical trials are being conducted in Mesquite, Texas."

Answered by AI

What is the projected participant count for this research project?

"Presently, this study is not recruiting patients. The trial was initially posted on March 30th, 2021, with the most recent update being on May 16th, 2022. There are 1007 other clinical trials for patients with obsessive-compulsive disorder and 6 trials for Troriluzole (BHV-4157) that are seeking participants."

Answered by AI

Has this kind of clinical trial been done before?

"Since 2016, Troriluzole (BHV-4157) has been the subject of active research. The first trial was sponsored by Biohaven Pharmaceuticals, Inc. and involved 141 participants. Following the successful completion of the first trial, Troriluzole (BHV-4157) received Phase 2 & 3 drug approval. There are currently 6 active studies involving Troriluzole (BHV-4157) taking place across 161 cities in 8 countries."

Answered by AI

Are there any specific eligibility requirements to take part in this research?

"Eligible participants for this study should have a formal diagnosis of obsessive-compulsive disorder, be between 18-65 years old. There is a total of 1200 slots available for this trial."

Answered by AI

Are we currently looking for new participants in this trial?

"Unfortunately, this particular clinical trial is no longer recruiting patients. The trial was posted on March 30th, 2021 and was updated on May 16th, 2022. However, there are 1007 other trials for obsessive-compulsive disorder and 6 for Troriluzole (BHV-4157) that are still actively recruiting participants."

Answered by AI

Who else is applying?

What state do they live in?
New Jersey
Florida
Texas
Other
How old are they?
18 - 65
What site did they apply to?
Stanford University
Qway Research, LLC
AIM Trials
Other
What portion of applicants met pre-screening criteria?
Did not meet criteria
Met criteria
How many prior treatments have patients received?
2
3+
0

Why did patients apply to this trial?

i want help with my OCD. I'm hoping to help others like me. My mental status is quickly deteriorating. I really need help.
PatientReceived no prior treatments
Looking through my email I accidentally fell upon this. I read the information and this looks good. I do have OCD .
PatientReceived no prior treatments
My OCD is out of control and I seriously need help to decrease stress of symptoms. My OCD is very debilitating and driving me nuts!
PatientReceived no prior treatments

What questions have other patients asked about this trial?

When does it start? What side effects are you seeing with medication, how much success are you seeing, how long does the medication take to work?
PatientReceived 2+ prior treatments
Recent research and studies
clinicaltrials.govStudy
Long-term Safety Study of Adjunctive Troriluzole in Subjects With Obsessive Compulsive Disorder
2021. "Long-term Safety Study of Adjunctive Troriluzole in Subjects With Obsessive Compulsive Disorder". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04708834.
All > Ocd
~312 spots leftby Jun 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top